Results 31 to 40 of about 1,081,297 (374)
A Vaccine Against Group B Streptococcus: Recent Advances [PDF]
Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World ...
Carreras-Abad, C+3 more
core +2 more sources
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
BACKGROUND Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age or older is unknown. METHODS In a randomized, double-blind,
M. Bonten+27 more
semanticscholar +1 more source
Background The first meningococcal serogroup C (MenC) conjugate vaccine was licensed in 1999 and introduced in the United Kingdom. Countries that have implemented the MenC vaccine since then in their national immunisation programmes use different ...
Kaaijk Patricia+4 more
doaj +1 more source
Background Salmonella Typhi is a major cause of fever in children in low- and middle-income countries. The recently WHO prequalified typhoid conjugate vaccine (TCV) was shown to be efficacious in a human challenge model but no efficacy trials in endemic ...
M. Shakya+22 more
semanticscholar +1 more source
Pneumococcal carriage, serotype distribution and risk factors in children with community-acquired pneumonia, 5 years after introduction of the 10-valent pneumococcal conjugate vaccine in Ethiopia [PDF]
Background: There is a scarcity of data on pneumococcal serotypes carried by children in Ethiopia. We studied pneumococcal nasopharyngeal carriage rate, serotypes, and risk factors among children with community acquired pneumonia (CAP).
Abebe, Workeabeba+7 more
core +1 more source
Background: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate ...
Helen L Stacey+15 more
semanticscholar +1 more source
Our study demonstrated real-world, direct effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia following introduction into a routine immunization program among adults aged ≥65 years, many of whom had
J. McLaughlin+11 more
semanticscholar +1 more source
Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system. [PDF]
Routine use of pneumococcal conjugate vaccines (PCVs) in developing countries is expected to lead to a significant reduction in childhood deaths. However, PCVs have been associated with replacement disease with non-vaccine serotypes.
Adegbola, Richard A+18 more
core +2 more sources
Background In April 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the infant immunisation schedule in England and Wales. Despite limited serotype replacement in invasive pneumococcal disease (IPD) during the first four post ...
J. Southern+7 more
semanticscholar +1 more source
Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea [PDF]
Streptococcus pneumoniae remains a leading cause of invasive infections including bacteremia and meningitis, as well as mucosal infections such as otitis media and pneumonia among children and adults.
Eun Hwa Choi+9 more
doaj +1 more source